PD-L1 is a Prognostic Biomarker in Resected NSCLC Patients with Moderate/high Smoking History and Elevated Serum SCCA Level

Programmed cell death-1 (PD-1) -targeted immunotherapy has become a promising treatment paradigm for patients with advanced non-small cell lung cancer (NSCLC). Clinical responses to checkpoint inhibition therapy in NSCLC have been associated with programmed death-1 ligand 1 (PD-L1) expression. Howev...

Descripción completa

Detalles Bibliográficos
Autores principales: Cao, Lianjing, Wang, Xinyue, Li, Shouying, Zhi, Qiongjie, Wang, Yuqian, Wang, Liuchun, Li, Kai, Jiang, Richeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5665041/
https://www.ncbi.nlm.nih.gov/pubmed/29158797
http://dx.doi.org/10.7150/jca.21118

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5665041/
https://www.ncbi.nlm.nih.gov/pubmed/29158797
http://dx.doi.org/10.7150/jca.21118

Ejemplares similares